Objective This paper intends to analyze the clinical efficacy of vedolizumab(VDZ)in the treatment of patients with inflammatory bowel disease(IBD).Methods Thirty-two IBD patients who received VDZ treatment at the First Affiliated Hospital of Air Force Medical University from February 2021 to May 2022 were selected and divided into the ulcerative colitis(UC)group(n=25)and the Crohn's disease(CD)group(n=7).The patients were administered once in weeks 0,2,6,14,22,30,38,46,and 54,respectively,followed up until week 52,and the clinical data were collected and analyzed.Results At weeks 6,14,22,and 52,the clinical response rates of the UC group are 40.0%,68.0%,72.0%,and 90.0%,respectively,and the clinical remission rates are 8.0%,16.0%,52.0%,and 80.0%,respectively,while the clinical response rates of the CD group are 14.3%,71.4%,85.7%,and 100%,respectively,and the clinical remission rates are 0,42.9%,57.1%,and 83.3%,respectively.At weeks 22 and 52,the endoscopic response rates of the UC group are 72.0%and 90.0%,respectively,and the endoscopic remission rates are 64.0%and 80.0%,respectively,while the endoscopic response rates of the CD group are 71.4%and 83.3%,respectively,and the endoscopic remission rates are 42.9%and 83.3%,respectively.At weeks 6,14,22,and 52,compared with before treatment,the red blood cell sedimentation rate(ESR),hypersensitive C-reactive protein(hs-CRP),and platelet count(PLT)of the UC group are significantly decreased(P＜0.05),while the hemoglobin(HGB)is significantly increased(P＜0.05).At weeks 6,14,22,and 52,compared with before treatment,the ESR of the CD group is significantly decreased(P＜0.05).At weeks 6 and 52,compared with before treatment,the hs-CRP of the CD group are significantly decreased(P＜0.05).At weeks 6,14,and 52,compared with before treatment,the PLT of the CD group is significantly decreased(P＜0.05).At weeks 14 and 52,compared with before treatment,the HGB of the CD group is significantly increased(P＜0.05).During the follow-up period,only one patient developed allergic rash,and the incidence of VDZ adverse reactions is 3.1%.Conclusion VDZ can effectively induce and maintain remission of IBD,with a lower incidence of adverse reactions and higher safety.
维普
万方数据
